-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Optimal timing for antihypertensive dosing: focus on valsartan
(2521) Views (527) Full article downloads
Authors: Ramón C Hermida, Diana E Ayala, Carlos Calvo
Published Date February 2007
Volume 2007:3(1) Pages 119 - 131
DOI: http://dx.doi.org/10.2147/TCRM.S
Ramón C Hermida1, Diana E Ayala1, Carlos Calvo2
1Bioengineering & Chronobiology Laboratories, University of Vigo, Campus Universitario, Vigo, 36200 Spain; 2Hypertension and Vascular Risk Unit, Hospital Clinico Universitario, Santiago de Compostela, 15706 Spain
Abstract: Some specific features of the 24 h blood pressure (BP) pattern are linked to the progressive injury of target tissues and the triggering of cardiac and cerebrovascular events. In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal BP mean (the diurnal/nocturnal ratio, an index of BP dipping) is deterministic of cardiovascular injury and risk. Normalization of the circadian BP pattern is considered to be an important clinical goal of pharmacotherapy because it may slow the advance of renal injury and avert end-stage renal failure. The chronotherapy of hypertension takes into account the epidemiology of the BP pattern, plus potential administration-time determinants of the pharmacokinetics and dynamics of antihypertensive medications, as a means of enhancing beneficial outcomes and/or attenuating or averting adverse effects. Thus, bedtime dosing with nifedipine gastrointestinal therapeutic system (GITS) is more effective than morning dosing, while also reducing significantly secondary effects. The dose-response curve, therapeutic coverage, and efficacy of doxazosin GITS are all markedly dependent on the circadian time of drug administration. Moreover, valsartan administration at bedtime as opposed to upon wakening results in improved diurnal/nocturnal ratio, a significant increase in the percentage of patients with controlled BP after treatment, and significant reductions in urinary albumin excretion and plasma fibrinogen. Chronotherapy provides a means of individualizing treatment of hypertension according to the circadian BP profile of each patient, and constitutes a new option to optimize BP control and reduce risk.
Keywords: valsartan, ambulatory blood pressure monitoring, dipper, nondipper, hypertension, chronotherapy, circadian rhythm
Readers of this article also read:
Tramadol extended-release in the management of chronic pain
Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction
Assessment and management of nutrition in older people and its importance to health
The role of herpesviruses in ocular infections
Reporting of results of interventional studies by the information service of the National Institutes of Health
Analgesic efficacy of oral gabapentin added to standard epidural corticosteroids in patients with failed back surgery
Using systematically observed clinical encounters (SOCEs) to assess medical students’ skills in clinical settings
Olmesartan/amlodipine: a review of its use in the management of hypertension
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




